Telesta Therapeutics (TSX:TST) - 500 Beiträge pro Seite
eröffnet am 02.12.14 12:49:52 von
neuester Beitrag 04.12.14 11:10:22 von
neuester Beitrag 04.12.14 11:10:22 von
Beiträge: 11
ID: 1.203.584
ID: 1.203.584
Aufrufe heute: 0
Gesamt: 30.708
Gesamt: 30.708
Aktive User: 0
ISIN: CA87953B1094 · WKN: A12F13
0,0900
EUR
-1,10 %
-0,0010 EUR
Letzter Kurs 01.11.16 Tradegate
Werte aus der Branche Biotechnologie
Wertpapier | Kurs | Perf. % |
---|---|---|
1,9000 | +59,66 | |
0,5922 | +44,44 | |
7,3500 | +43,84 | |
11,690 | +40,84 | |
0,7000 | +36,69 |
Wertpapier | Kurs | Perf. % |
---|---|---|
10,110 | -13,44 | |
8,2200 | -13,47 | |
7,6100 | -17,20 | |
1,6100 | -18,27 | |
2,1200 | -21,77 |
Telesta Therapeutics Announces Key Clinical & Corporate Updates
MONTREAL, Dec. 1, 2014 /CNW/ - Telesta Therapeutics Inc. (TSX: TST; PNK: BNHLF) (Formerly Bioniche Life Sciences Inc. TST:BNC) today affirmed that they remain on track with their internal objective of filing a Biologics License Application (BLA) for marketing approval with the US Food and Drug Administration (FDA) for MCNA 1 prior to March 31, 2015. Two recent key accomplishments include the completion of both a pre-BLA meeting with the US FDA and a mock-audit of Telesta's MCNA manufacturing facility. As the result of the pre-BLA meeting, Telesta received written answers and verbal feedback to a number of clinical, manufacturing and regulatory items related to the filing of their BLA while the manufacturing "mock-audit" saw a third party firm complete a detailed and exhaustive review intended to simulate the type of audit that Telesta is expected to be subject to, by the FDA, during the course of a BLA review process.
Commenting on these achievements, Dr. Michael Berendt, Chief Executive Officer and Chief Scientist noted that: "We will continue to challenge ourselves and our expert consultants to ensure that the BLA that we ultimately file, will be the best BLA that we can produce. At this critical juncture in our history, nothing is more important than achieving our ultimate goal of delivering to non-muscle invasive bladder cancer patients who have failed first line BCG therapy, a new and efficacious therapeutic option."
In parallel, Telesta expects to conclude their third party assessment of the market opportunity for MCNA, in the United States, in the weeks to come. This market assessment, where qualitative and quantitative primary market research was conducted with payers (managed care organizations/decision makers both from the private and public sector) and urologists (community urologists and key opinion leaders), will address issues such as market size, pricing/pricing strategy and market access context/reimbursement potential for MCNA. These data will be key in assisting Telesta to make informed decisions concerning overall market potential and optimal licensing/partnering and/or commercial development strategy.
Telesta also announced today that its Board of Directors has accepted the resignation of Mr Greg Gubitz as a Director of the Company. Mr. James Rae, Chairman of the Board of Directors stated, "While Greg was a positive and thoughtful voice at the Board and Board committee levels, the Board must acknowledge the voting results of the November 12th, AGM. We will be conducting a search for a new Director in the weeks to come.
From today, going forward, Telesta Therapeutics will trade on the Toronto Stock Exchange (TSX) under the new ticker "TST" (TSX:TST). Telesta Therapeutics will also be announcing the launch of its new website in the weeks to come.
MONTREAL, Dec. 1, 2014 /CNW/ - Telesta Therapeutics Inc. (TSX: TST; PNK: BNHLF) (Formerly Bioniche Life Sciences Inc. TST:BNC) today affirmed that they remain on track with their internal objective of filing a Biologics License Application (BLA) for marketing approval with the US Food and Drug Administration (FDA) for MCNA 1 prior to March 31, 2015. Two recent key accomplishments include the completion of both a pre-BLA meeting with the US FDA and a mock-audit of Telesta's MCNA manufacturing facility. As the result of the pre-BLA meeting, Telesta received written answers and verbal feedback to a number of clinical, manufacturing and regulatory items related to the filing of their BLA while the manufacturing "mock-audit" saw a third party firm complete a detailed and exhaustive review intended to simulate the type of audit that Telesta is expected to be subject to, by the FDA, during the course of a BLA review process.
Commenting on these achievements, Dr. Michael Berendt, Chief Executive Officer and Chief Scientist noted that: "We will continue to challenge ourselves and our expert consultants to ensure that the BLA that we ultimately file, will be the best BLA that we can produce. At this critical juncture in our history, nothing is more important than achieving our ultimate goal of delivering to non-muscle invasive bladder cancer patients who have failed first line BCG therapy, a new and efficacious therapeutic option."
In parallel, Telesta expects to conclude their third party assessment of the market opportunity for MCNA, in the United States, in the weeks to come. This market assessment, where qualitative and quantitative primary market research was conducted with payers (managed care organizations/decision makers both from the private and public sector) and urologists (community urologists and key opinion leaders), will address issues such as market size, pricing/pricing strategy and market access context/reimbursement potential for MCNA. These data will be key in assisting Telesta to make informed decisions concerning overall market potential and optimal licensing/partnering and/or commercial development strategy.
Telesta also announced today that its Board of Directors has accepted the resignation of Mr Greg Gubitz as a Director of the Company. Mr. James Rae, Chairman of the Board of Directors stated, "While Greg was a positive and thoughtful voice at the Board and Board committee levels, the Board must acknowledge the voting results of the November 12th, AGM. We will be conducting a search for a new Director in the weeks to come.
From today, going forward, Telesta Therapeutics will trade on the Toronto Stock Exchange (TSX) under the new ticker "TST" (TSX:TST). Telesta Therapeutics will also be announcing the launch of its new website in the weeks to come.
sehr interessanter Wert ;-)
könnte ein Tenbagger werden :-)
könnte ein Tenbagger werden :-)
Antwort auf Beitrag Nr.: 48.471.983 von Roboterotze am 02.12.14 12:49:52Klingt vielversprechend
Antwort auf Beitrag Nr.: 48.482.258 von Rainolaus am 03.12.14 18:38:03....und vor allem wie aus dem Nichts erschienen
Aber mal Spass beiseite....
Als nächsten Kurstreiber sehe ich die Veröffentlichung des Markt- bzw. Umsatzpotentials in den "kommenden Wochen". Bis dahin wird sie wohl weiter bei 0,21-0,23 CAD verweilen...
Aber mal Spass beiseite....
Als nächsten Kurstreiber sehe ich die Veröffentlichung des Markt- bzw. Umsatzpotentials in den "kommenden Wochen". Bis dahin wird sie wohl weiter bei 0,21-0,23 CAD verweilen...
Ja dann mal auf eine grüne Zeit =)
moinsen,
jetzt findet es auch die suche
der bericht sollte noch vor weihnachten kommen
jetzt findet es auch die suche
der bericht sollte noch vor weihnachten kommen
Damit man`s schnell mal eben findet, auf Seite 1.
TMX Money Telesta
http://web.tmxmoney.com/quote.php?qm_symbol=TST
Kurs Deutschland
http://www.onvista.de/aktien/handelsplaetze/TELESTA-THERAPEU…
http://www.tradegate.de/orderbuch.php?isin=CA87953B1094
TMX Money Telesta
http://web.tmxmoney.com/quote.php?qm_symbol=TST
Kurs Deutschland
http://www.onvista.de/aktien/handelsplaetze/TELESTA-THERAPEU…
http://www.tradegate.de/orderbuch.php?isin=CA87953B1094
der alte Fred wurde nun mit TST verknüpft, bitte da weiterschreiben
!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: Auszug aus Individualkommunikation, nicht verifizierbare Inhalte, private Mails gehören nicht ins Forum
Antwort auf Beitrag Nr.: 48.486.260 von allin123 am 04.12.14 10:55:24Oki doki - ich schreib mal dem MOD, dass er diesen hier schließt..
Hallo liebe User,
auf Wunsch des Threaderöffners schliessen wir diesen Thread.
Eine aktuelle Diskussion findet ihr unter
Thread: Diskussion zu Telesta Therapeutics -- ehem Bioniche Life
Vielen Dank !
Freundliche Grüße CloudMOD
auf Wunsch des Threaderöffners schliessen wir diesen Thread.
Eine aktuelle Diskussion findet ihr unter
Thread: Diskussion zu Telesta Therapeutics -- ehem Bioniche Life
Vielen Dank !
Freundliche Grüße CloudMOD
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
Wertpapier | Perf. % |
---|---|
-0,05 | |
-1,53 | |
-5,17 | |
+6,46 | |
0,00 | |
-0,94 | |
-0,78 | |
0,00 | |
-2,01 | |
0,00 |
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
63 | ||
55 | ||
46 | ||
38 | ||
20 | ||
14 | ||
12 | ||
11 | ||
10 | ||
10 |